Notice of Intent To Grant an Exclusive, Co-Exclusive or Partially Exclusive Patent License, 32284-32285 [2021-12756]
Download as PDF
<![CDATA[
lotter on DSK11XQN23PROD with NOTICES1
32284
Federal Register / Vol. 86, No. 115 / Thursday, June 17, 2021 / Notices
Blanton, M.D., 43 FR 27,616, 27,617
(1978).
This rule derives from the text of two
provisions of the CSA. First, Congress
defined the term ‘‘practitioner’’ to mean
‘‘a physician . . . or other person
licensed, registered, or otherwise
permitted, by . . . the jurisdiction in
which he practices . . . , to distribute,
dispense, . . . [or] administer . . . a
controlled substance in the course of
professional practice.’’ 21 U.S.C.
802(21). Second, in setting the
requirements for obtaining a
practitioner’s registration, Congress
directed that ‘‘[t]he Attorney General
shall register practitioners . . . if the
applicant is authorized to dispense . . .
controlled substances under the laws of
the State in which he practices.’’ 21
U.S.C. 823(f). Because Congress has
clearly mandated that a practitioner
possess state authority in order to be
deemed a practitioner under the CSA,
the DEA has held repeatedly that
revocation of a practitioner’s registration
is the appropriate sanction whenever he
is no longer authorized to dispense
controlled substances under the laws of
the state in which he practices. See, e.g.,
James L. Hooper, 76 FR at 71,371–72;
Sheran Arden Yeates, M.D., 71 FR
39,130, 39,131 (2006); Dominick A.
Ricci, M.D., 58 FR 51,104, 51,105 (1993);
Bobby Watts, M.D., 53 FR 11,919, 11,920
(1988); Frederick Marsh Blanton, 43 FR
at 27,617.
Under Nebraska law, ‘‘[d]ispense
means to deliver a controlled substance
to an ultimate user or a research subject
pursuant to a medical order issued by a
practitioner authorized to prescribe,
including the packaging, labeling, or
compounding necessary to prepare the
controlled substance for such delivery.’’
Neb. Rev. Stat. § 28–401(8) (Westlaw,
Current through legislation effective
May 6, 2021). Further, ‘‘[p]ractitioner
means a physician . . . or any other
person licensed, registered, or otherwise
permitted to distribute, dispense,
prescribe, conduct research with respect
to, or administer a controlled substance
in the course of practice or research in
this state . . . .’’ Id. at § 28–401(21).
Because Registrant is not currently
licensed as a physician, or otherwise
licensed, in Nebraska, he is not
authorized to dispense controlled
substances in Nebraska.
Here, the undisputed evidence in the
record is that Registrant currently lacks
authority to practice medicine in
Nebraska. As already discussed, a
physician must be a licensed
practitioner to dispense a controlled
substance in Nebraska. Thus, because
Registrant lacks authority to practice
medicine in Nebraska and, therefore, is
VerDate Sep<11>2014
18:41 Jun 16, 2021
Jkt 253001
not authorized to handle controlled
substances in Nebraska, Registrant is not
eligible to maintain a DEA registration.
Accordingly, I will order that
Registrant’s DEA registration be
revoked.
Order
Pursuant to 28 CFR 0.100(b) and the
authority vested in me by 21 U.S.C.
824(a), I hereby revoke DEA Certificate
of Registration No. FK4149882 issued to
Tareq A. Khedir Al-Tiae, M.D. Further,
pursuant to 28 CFR 0.100(b) and the
authority vested in me by 21 U.S.C.
823(f), I hereby deny any pending
application of Tareq A. Khedir Al-Tiae,
M.D., to renew or modify this
registration, as well as any other
pending application of Tareq A. Khedir
Al-Tiae M.D., for additional registration
in Nebraska. This Order is effective July
19, 2021.
D. Christopher Evans,
Acting Administrator.
[FR Doc. 2021–12755 Filed 6–16–21; 8:45 am]
BILLING CODE 4410–09–P
North Normandy Drive, Petersburg,
Virginia 23805–2380, applied to be
registered as a bulk manufacturer of the
following basic class(es) of controlled
substance(s):
Controlled substance
Methylphenidate ...........
Levomethorphan ...........
Levorphanol ..................
Morphine .......................
Thebaine .......................
Noroxymorphone ..........
Tapentadol ....................
Drug
code
1724
9210
9220
9300
9333
9668
9780
Schedule
II
II
II
II
II
II
II
The company plans to bulk
manufacture the listed controlled
substances for the internal use
intermediates or for sale to its
customers. The company plans to
manufacture the above-listed controlled
substances in bulk for distribution to its
customers. No other activities for these
drug codes are authorized for this
registration.
William T. McDermott,
Assistant Administrator.
[FR Doc. 2021–12812 Filed 6–16–21; 8:45 am]
DEPARTMENT OF JUSTICE
BILLING CODE P
Drug Enforcement Administration
NATIONAL AERONAUTICS AND
SPACE ADMINISTRATION
[Docket No. DEA–852]
Bulk Manufacturer of Controlled
Substances Application: AMPAC Fine
Chemicals Virginia, LLC
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
AGENCY:
PO 00000
Frm 00041
Fmt 4703
Sfmt 4703
Notice of Intent To Grant an Exclusive,
Co-Exclusive or Partially Exclusive
Patent License
National Aeronautics and
Space Administration.
ACTION: Notice of intent to grant
exclusive, co-exclusive or partially
exclusive patent license.
AGENCY:
AMPAC Fine Chemicals
Virginia, LLC. has applied to be
registered as a bulk manufacturer of
basic class(es) of controlled
substance(s). Refer to SUPPLEMENTARY
INFORMATION listed below for further
drug information.
DATES: Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before August 16, 2021. Such persons
may also file a written request for a
hearing on the application on or before
August 16, 2021.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152.
SUPPLEMENTARY INFORMATION: In
accordance with 21 CFR 1301.33(a), this
is notice that on May 5, 2021, AMPAC
Fine Chemicals Virginia, LLC., 2820
SUMMARY:
[Notice: (21–035)]
NASA hereby gives notice of
its intent to grant an exclusive, coexclusive or partially exclusive patent
license to practice the inventions
described and claimed in the patents
and/or patent applications listed in
SUPPLEMENTARY INFORMATION below.
DATES: The prospective exclusive, coexclusive or partially exclusive license
may be granted unless NASA receives
written objections including evidence
and argument, no later than July 2, 2021
that establish that the grant of the
license would not be consistent with the
requirements regarding the licensing of
federally owned inventions as set forth
in the Bayh-Dole Act and implementing
regulations. Competing applications
completed and received by NASA no
later than July 2, 2021 will also be
treated as objections to the grant of the
contemplated exclusive, co-exclusive or
SUMMARY:
E:\FR\FM\17JNN1.SGM
17JNN1
Federal Register / Vol. 86, No. 115 / Thursday, June 17, 2021 / Notices
partially exclusive license. Objections
submitted in response to this notice will
not be made available to the public for
inspection and, to the extent permitted
by law, will not be released under the
Freedom of Information Act.
FOR FURTHER INFORMATION CONTACT:
Written objections relating to the
prospective license or requests for
further information may be submitted to
Agency Counsel for Intellectual
Property, NASA Headquarters at Email:
hq-patentoffice@mail.nasa.gov.
Questions may be directed to Helen
Galus at (202) 358–3437.
SUPPLEMENTARY INFORMATION: NASA
intends to grant an exclusive, coexclusive, or partially exclusive patent
license in the United States to practice
the inventions described and claimed
in: US 8,735,116 B2, High-Density Spot
Seeding for Tissue Model Formation
and US 9,243,223 B2, High-Density Spot
Seeding for Tissue Model Formation to
BSK Health Partners, LLC. having its
principal place of business in North
Richland Hills, Texas. The fields of use
may be limited. NASA has not yet made
a final determination to grant the
requested license and may deny the
requested license even if no objections
are submitted within the comment
period.
This notice of intent to grant an
exclusive, co-exclusive or partially
exclusive patent license is issued in
accordance with 35 U.S.C. 209(e) and 37
CFR 404.7(a)(1)(i). The patent rights in
these inventions have been assigned to
the United States of America as
represented by the Administrator of the
National Aeronautics and Space
Administration. The prospective license
will comply with the requirements of 35
U.S.C. 209 and 37 CFR 404.7.
Information about other NASA
inventions available for licensing can be
found online at https://
technology.nasa.gov.
Helen M. Galus,
Agency Counsel for Intellectual Property.
BILLING CODE 7510–13–P
NUCLEAR REGULATORY
COMMISSION
lotter on DSK11XQN23PROD with NOTICES1
Advisory Committee on the Medical
Uses of Isotopes: Meeting Notice
U.S. Nuclear Regulatory
Commission.
ACTION: Notice of meeting.
AGENCY:
The U.S. Nuclear Regulatory
Commission (NRC) will convene a
public teleconference meeting of the
VerDate Sep<11>2014
18:41 Jun 16, 2021
Jkt 253001
The teleconference meeting will
be held on Thursday, July 15, 2021, 1:00
p.m. to 3:00 p.m. Eastern Daylight Time.
DATES:
Date
Webinar information
July 15, 2021 ....
Link: https://
usnrc.webex.com.
Event number: 199 085
4780.
2. Questions and comments from
members of the public will be permitted
during the meeting, at the discretion of
the ACMUI Chairman.
3. The draft transcript and meeting
summary will be available on ACMUI’s
website https://www.nrc.gov/readingrm/doc-collections/acmui/meetings/
2021.html on or about August 31, 2021.
4. Persons who require special
services, such as those for the hearing
impaired, should notify Ms. Jamerson of
their planned participation.
This meeting will be held in
accordance with the Atomic Energy Act
of 1954, as amended (primarily Section
161a); the Federal Advisory Committee
Act (5 U.S.C. App); and the
Commission’s regulations in 10 CFR
part 7.
Dated at Rockville, Maryland this 14th day
of June, 2021.
For the U.S. Nuclear Regulatory
Commission.
Russell E. Chazell,
Federal Advisory Committee Management
Officer.
[FR Doc. 2021–12767 Filed 6–16–21; 8:45 am]
BILLING CODE 7590–01–P
Public Participation: The meeting will
also be held as a webinar. Any member
of the public who wishes to participate
in any portion of this meeting should
register in advance of the meeting by
accessing the provided link and event
number above. Upon successful
registration, an email confirmation will
be generated providing the telephone
bridge line and a link to join the
webinar on the day of the meeting.
Members of the public should also
monitor the NRC’s Public Meeting
Schedule at https://www.nrc.gov/pmns/
mtg for any meeting updates. If there are
any questions regarding the meeting,
please contact Ms. Jamerson using the
information below.
Contact Information: Kellee Jamerson,
email: Kellee.Jamerson@nrc.gov,
telephone: 301–415–7408.
Conduct of the Meeting
[FR Doc. 2021–12756 Filed 6–16–21; 8:45 am]
SUMMARY:
Advisory Committee on the Medical
Uses of Isotopes (ACMUI) on July 15,
2021, to discuss the ACMUI
Subcommittee on Extravasations and
Medical Event Reporting draft report on
the NRC staff’s preliminary evaluation
of whether extravasations merits a
change in medical event reporting. The
meeting agenda is subject to change.
Meeting information, including a copy
of the agenda and related documents,
will be available on the ACMUI’s
Meetings and Related Documents web
page at https://www.nrc.gov/reading-rm/
doc-collections/acmui/meetings/
2021.html. The agenda and related
meeting documents may also be
obtained by contacting Ms. Kellee
Jamerson using the information below.
32285
The ACMUI Chair, Darlene F. Metter,
M.D., will preside over the meeting. Dr.
Metter will conduct the meeting in a
manner that will facilitate the orderly
conduct of business. The following
procedures apply to public participation
in the meeting:
1. Persons who wish to provide a
written statement should submit an
electronic copy to Ms. Jamerson at the
contact information listed above. All
written statements must be received by
July 12, 2021, three business days prior
to the meeting, and must pertain to the
topics on the agenda for the meeting.
PO 00000
Frm 00042
Fmt 4703
Sfmt 4703
NUCLEAR REGULATORY
COMMISSION
[Docket No. 40–8907; NRC–2019–0026]
United Nuclear Corporation Church
Rock Project
Nuclear Regulatory
Commission.
ACTION: Draft environmental impact
statement; reopening of comment
period.
AGENCY:
On November 13, 2020, the
U.S. Nuclear Regulatory Commission
(NRC) issued for public comment a draft
Environmental Impact Statement (EIS)
for United Nuclear Corporation’s (UNC)
license amendment request. The public
comment period closed on May 27,
2021. The NRC has decided to re-open
the public comment period to allow
more time for members of the public to
develop and submit their comments.
UNC is requesting authorization to
amend its license (SUA–1475) to
excavate approximately 1 million cubic
yards (CY) of mine waste from the
Northeast Church Rock Mine Site and
dispose of it at the existing mill site in
McKinley County, New Mexico. The
NRC plans to hold a public meeting in
the future to promote full understanding
of the contemplated action and facilitate
public comment.
DATES: The comment period for the
document published on November 13,
SUMMARY:
E:\FR\FM\17JNN1.SGM
17JNN1
]]>Agencies
[Federal Register Volume 86, Number 115 (Thursday, June 17, 2021)]
[Notices]
[Pages 32284-32285]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-12756]
=======================================================================
-----------------------------------------------------------------------
NATIONAL AERONAUTICS AND SPACE ADMINISTRATION
[Notice: (21-035)]
Notice of Intent To Grant an Exclusive, Co-Exclusive or Partially
Exclusive Patent License
AGENCY: National Aeronautics and Space Administration.
ACTION: Notice of intent to grant exclusive, co-exclusive or partially
exclusive patent license.
-----------------------------------------------------------------------
SUMMARY: NASA hereby gives notice of its intent to grant an exclusive,
co-exclusive or partially exclusive patent license to practice the
inventions described and claimed in the patents and/or patent
applications listed in SUPPLEMENTARY INFORMATION below.
DATES: The prospective exclusive, co-exclusive or partially exclusive
license may be granted unless NASA receives written objections
including evidence and argument, no later than July 2, 2021 that
establish that the grant of the license would not be consistent with
the requirements regarding the licensing of federally owned inventions
as set forth in the Bayh-Dole Act and implementing regulations.
Competing applications completed and received by NASA no later than
July 2, 2021 will also be treated as objections to the grant of the
contemplated exclusive, co-exclusive or
[[Page 32285]]
partially exclusive license. Objections submitted in response to this
notice will not be made available to the public for inspection and, to
the extent permitted by law, will not be released under the Freedom of
Information Act.
FOR FURTHER INFORMATION CONTACT: Written objections relating to the
prospective license or requests for further information may be
submitted to Agency Counsel for Intellectual Property, NASA
Headquarters at Email: [email protected]. Questions may be
directed to Helen Galus at (202) 358-3437.
SUPPLEMENTARY INFORMATION: NASA intends to grant an exclusive, co-
exclusive, or partially exclusive patent license in the United States
to practice the inventions described and claimed in: US 8,735,116 B2,
High-Density Spot Seeding for Tissue Model Formation and US 9,243,223
B2, High-Density Spot Seeding for Tissue Model Formation to BSK Health
Partners, LLC. having its principal place of business in North Richland
Hills, Texas. The fields of use may be limited. NASA has not yet made a
final determination to grant the requested license and may deny the
requested license even if no objections are submitted within the
comment period.
This notice of intent to grant an exclusive, co-exclusive or
partially exclusive patent license is issued in accordance with 35
U.S.C. 209(e) and 37 CFR 404.7(a)(1)(i). The patent rights in these
inventions have been assigned to the United States of America as
represented by the Administrator of the National Aeronautics and Space
Administration. The prospective license will comply with the
requirements of 35 U.S.C. 209 and 37 CFR 404.7.
Information about other NASA inventions available for licensing can
be found online at https://technology.nasa.gov.
Helen M. Galus,
Agency Counsel for Intellectual Property.
[FR Doc. 2021-12756 Filed 6-16-21; 8:45 am]
BILLING CODE 7510-13-P
